Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...
In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...
Verywell Health on MSN10d
7 Common Causes of Pulmonary Arterial HypertensionPulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...
MedPage Today on MSN6d
Sotatercept Helps the Sickest Patients With Pulmonary Arterial HypertensionCHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...
Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...
Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...
Tuko News on MSN18h
Nairobi mother of 2 requests urgent help to raise KSh 8.5m for life-saving treatment abroadAlice Wanjiku Kirumba, a 35-year-old mother of two, is seeking to raise KSh 8.5 million to undergo treatment for Chronic ...
The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.
A small, multi-country analysis of women of child-rearing age has found that these patients experience limits on activities ...
Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback